Sofantinib acts on fibroblast growth factor receptor and vascular endothelial cell growth factor receptor to inhibit tumor growth, and can treat inoperable progressive nonfunctional, locally metastatic, or advanced, well-differentiated neuroendocrine tumors of non-pancreatic origin. Adverse reactions such as hypertension, diarrhea, proteinuria, abdominal pain, nausea and vomiting, elevated blood bilirubin, fatigue, elevated blood uric acid, hemorrhage, lowered blood albumin, skeletal muscle pain, peripheral edema, anemia, lowered blood calcium, elevated blood triglyceride, and elevated blood thyroid stimulating hormone can occur after administration of the drug. The patient’s blood pressure should be controlled within 140/90 mmHg before and during drug administration; liver function should be tested before drug administration, every 2 weeks for the first two months after drug administration, and then every month or according to the clinical situation. The following conditions are contraindicated: hypersensitivity to the drug; pregnancy and lactation; severe active bleeding; unhealed gastrointestinal perforation or peptic fistula; active peptic ulcer; severe hepatic insufficiency. The drug is not recommended for patients under 18 years of age. Use the drug with caution in elderly patients. Contraception is recommended for female patients of childbearing age for the duration of the medication and for 1 month after discontinuation of the medication, and for male patients for the duration of the medication and for 3 months after discontinuation of the medication. If you need to use the drug, please be sure to follow the doctor’s instructions strictly, do not use the drug on your own.